Mechanisms of action of flavopiridol

Critical Reviews in Oncology/hematology
H H Sedlacek

Abstract

Flavopiridol inhibits phosphokinases. Its activity is strongest on cyclin dependent kinases (cdk-1, -2, -4, -6, -7) and less on receptor tyrosine kinases (EGFR), receptor associates tyrosine kinases (pp60 Src) and on signal transducing kinases (PKC and Erk-1). Although the inhibiting activity of flavopiridol is strongest for cdk, the cytotoxic activity of flavopiridol is not limited to cycling cells. Resting cells are also killed. This fact suggests that inhibition of cdks involved in the control of cell cycle is not the only mechanism of action. Inhibition of cdk's with additional functions (i.e. involved in the control of transcription or function of proteins that do not control cell cycle) may contribute to the antitumoral effect. Moreover, direct and indirect inhibition of receptor activation (EGFR) and/or a direct inhibition of kinases (pp60 Src, PKC, Erk-1) involved in the signal transduction pathway could play a role in the antiproliferative activity of flavopiridol. From pharmacokinetic data in patients it can be concluded that the inhibitory activity (IC50) of flavopiridol on these kinases is in the range of concentrations that might be achieved intracellularly after systemic application of non-toxic doses of flavopiri...Continue Reading

References

Nov 18, 1992·Journal of the National Cancer Institute·G KaurE Sausville
Jan 1, 1992·Annual Review of Cell Biology·C F Higgins
Sep 1, 1992·Cancer Metastasis Reviews·J A Hickman
Feb 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·X L QuianM I Greene
Jan 1, 1992·Annual Review of Biochemistry·E H Blackburn
Jan 2, 1992·International Journal of Cancer. Journal International Du Cancer·E AflaloY Weinstein
Jan 1, 1991·Pharmacology & Therapeutics·S Stabel, P J Parker
Dec 1, 1991·Pharmacology & Therapeutics·K J ScanlonT Funato
Apr 11, 1991·Nature·T MotokuraA Arnold
Nov 11, 1991·The EMBO Journal·B DucommunG Draetta
Jul 30, 1991·International Journal of Cancer. Journal International Du Cancer·Y SakanoueJ Utsunomiya
Jul 5, 1991·Science·M HollsteinC C Harris
Dec 31, 1990·Biochemical and Biophysical Research Communications·W SatoT Tsuruo
Jun 6, 1991·Nature·A J LevineC A Finlay
Apr 1, 1990·British Journal of Cancer·P Barrett-LeeR C Coombes
Jun 1, 1989·European Journal of Biochemistry·R M Marais, P J Parker
Jan 1, 1989·Annual Review of Biochemistry·U KikkawaY Nishizuka
Aug 1, 1989·Molecular and Cellular Endocrinology·P J ParkerC Webster
Jan 1, 1985·Annual Review of Biochemistry·T Hunter, J A Cooper
Jan 1, 1987·Annual Review of Biochemistry·G Carpenter
Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R L FineB A Chabner
Mar 3, 1986·FEBS Letters·A DePaoli-RoachS S Smith
Dec 1, 1995·Nature Medicine·M StraussJ Bartek
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·D K LuttrellT M Gilmer

❮ Previous
Next ❯

Citations

May 30, 2008·Cancer Chemotherapy and Pharmacology·Cornel J PhillipVarsha Gandhi
Apr 7, 2010·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Lukas K FilakBernhard K Keppler
Mar 17, 2005·Breast Cancer Research and Treatment·Shadan AliPhilip A Philip
May 10, 2006·Investigational New Drugs·Basil F El-RayesPhilip A Philip
Jan 31, 2004·Current Oncology Reports·Yun Dai, Steven Grant
Aug 21, 2007·Current Oncology Reports·Asher A Chanan-Khan
Aug 15, 2009·Current Oncology Reports·Amir T Fathi, Judith E Karp
Jun 19, 2004·Leukemia Research·Claire QuineyChristian Billard
Mar 26, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Steven Grant, John D Roberts
Nov 5, 2003·Progress in Cell Cycle Research·Peter M FischerLaurent Meijer
Oct 3, 2002·British Journal of Haematology·J TopalyS Fruehauf
Jan 28, 2006·Nucleosides, Nucleotides & Nucleic Acids·Jennifer Sigmond, Godfridus J Peters
Jul 30, 2010·Assay and Drug Development Technologies·Anne-Kathrin ScholzBodo M H Lange
May 29, 2004·Anti-cancer Drugs·Elizabeth W Newcomb
Nov 4, 2009·American Journal of Clinical Oncology·Houman M FekrazadIan Rabinowitz
Jan 22, 2011·Sarcoma·Rachel ConyersDavid M Thomas
Dec 17, 2004·Human Genomics·Lee Makowski, Diane J Rodi
Apr 24, 2009·PLoS Biology·Erin K McCarthy CampbellBob Goldstein
Jul 30, 2011·PloS One·Huda H Al-KhalafAbdelilah Aboussekhra
Dec 1, 2009·Future Medicinal Chemistry·Józefa Węsierska-GądekVladimír Kryštof
Aug 25, 2007·Pharmacogenomics·Georgios GiamasUwe Knippschild
Nov 8, 2013·BioMed Research International·Mohammad Zahid KamranRajiv P Gude
Nov 26, 2015·Journal of Biomolecular Structure & Dynamics·Bhumika RayRanjana Mehrotra
Jul 15, 2015·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-WołowiecTadeusz Robak
Jul 14, 2010·Best Practice & Research. Clinical Haematology·Rong Chen, William Plunkett
Jun 5, 2007·Critical Reviews in Oncology/hematology·David Michod, Christian Widmann
Nov 3, 2015·Leukemia Research·Joshua F Zeidner, Judith E Karp
Dec 1, 2004·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·S SatoM Tsurumaru
Feb 21, 2004·British Journal of Pharmacology·Anna Maria CanudasMercè Pallàs
Nov 15, 2007·Pediatric Blood & Cancer·Kelly M JackmanStephen P Hunger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis